<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161199</url>
  </required_header>
  <id_info>
    <org_study_id>H52899-34904-01</org_study_id>
    <nct_id>NCT01161199</nct_id>
  </id_info>
  <brief_title>The Use of Leukapheresis to Support HIV Pathogenesis Studies</brief_title>
  <official_title>The Use of Leukapheresis to Support HIV Pathogenesis Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the dramatic improvements that have resulted from combination antiretroviral&#xD;
      treatment, long-term efficacy, toxicity, cost, and the requirements for life-long adherence&#xD;
      remain as formidable challenges. Also, there is emerging consensus that persistent&#xD;
      HIV-associated disease occurs during long-term highly active antiretroviral therapy (HAART).&#xD;
      This disease may be due to either direct drug-toxicity and/or persistent viral&#xD;
      replication/production and/or persistent HIV-associated inflammation. Hence, strategies aimed&#xD;
      at achieving complete viral eradication may be needed in order to fully restore health among&#xD;
      HIV infected individuals. Even if complete eradication proves impossible-as most believe to&#xD;
      be the case-a less rigorous but still desirable outcome might be achieving durable control of&#xD;
      virus in the absence of therapy. That a &quot;functional&quot; cure is possible is well illustrated by&#xD;
      those rare individuals who are able to durably control replication competent virus in the&#xD;
      absence of therapy (&quot;elite&quot; controllers).&#xD;
&#xD;
      A more complete understanding of the relationship between inflammation and viral persistence&#xD;
      is necessary before more rationale studies of HIV eradication can be designed. Also, a well&#xD;
      validated high through-put virologic assay needs to be developed that can estimate the size&#xD;
      of the latent reservoir. Since the level of replication competent virus in long-term treated&#xD;
      patients (and in elite controllers) is very small (&lt; 1% of CD4 cells harbor HIV), large&#xD;
      numbers of CD4+ T cells most be obtained from study participants in order to routinely&#xD;
      isolate and quantify virus persistence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV DNA and RNA</measure>
    <time_frame>Baseline and 6-12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Untreated non-controllers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Elite controllers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HAART-suppressed</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.</description>
    <arm_group_label>Elite controllers</arm_group_label>
    <arm_group_label>HAART-suppressed</arm_group_label>
    <arm_group_label>Untreated non-controllers</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CD4+ T cells Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients on long-term antiretroviral therapy, untreated patients, and elite&#xD;
        controllers will be studied.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV seropositive&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Willing to undergo blood sampling and/or leukapheresis&#xD;
&#xD;
          -  Meeting one of the following criteria: (1) on stable highly active antiretroviral&#xD;
             therapy (HAART) with a recent undetectable viral load (&lt; 50 copies/mL) (&quot;HAART&#xD;
             suppressed&quot;), (2) antiretroviral untreated with an undetectable viral load (&lt; 50&#xD;
             copies/mL) (&quot;elite&quot; controllers) and (3) antiretroviral untreated with a detectable&#xD;
             viral load (&gt; 1000 copies/mL) (&quot;non-controllers&quot;)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known anemia (HIV+ males Hct&lt;34; females Hct&lt;32) or contraindication to donating blood&#xD;
&#xD;
          -  Blood coagulation disorder (including bleeding tendency or problems in past with blood&#xD;
             clots)&#xD;
&#xD;
          -  Platelets &lt; 50,000/mm3&#xD;
&#xD;
          -  PTT &gt; 2x ULN&#xD;
&#xD;
          -  INR &gt; 1.5&#xD;
&#xD;
          -  Albumin &lt; 2.0 g/dL&#xD;
&#xD;
          -  ALT &gt; 5x ULN&#xD;
&#xD;
          -  AST &gt; 5x ULN&#xD;
&#xD;
          -  Biopsy-proven or clinical diagnosis of cirrhosis&#xD;
&#xD;
          -  Weight &lt;120 lb&#xD;
&#xD;
          -  High blood pressure &gt; 160/100&#xD;
&#xD;
          -  Low blood pressure &lt; 100/70&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Deeks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Deeks, MD</last_name>
    <phone>415-476-4082</phone>
    <phone_ext>404</phone_ext>
    <email>Steven.Deeks@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Deeks, MD</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>404</phone_ext>
      <email>Steven.Deeks@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Deeks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>latent reservoir</keyword>
  <keyword>functional cure</keyword>
  <keyword>leukapheresis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

